Studies have suggested that robust MAPK pathway suppression is required for response in BRAF V600E cancers and acquired resistance to BRAF inhibitor combinations involve reactivation of the MAPK pathway (Ahronian et al., 2015). This evidence concerns the gene BRAF and cancer.